It is time to move forward with Waldenström!
In this issue of Blood, Roccaro et al demonstrate high expression of C-X-C chemokine receptor type 4 (CXCR4) mutation in Waldenström macroglobulinemia (WM), a marker of tumor aggression and drug resistance. In vivo analysis with an anti-CXCR4 antibody reversed this aggression, setting the stage for prospective studies in this forgotten disease.